The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
IHC (PFA fixed)
Application notesICC/IF: 1/200.
Immunohistochemistry (PFA fixed): Use at an assay dependent dilution (See PMID: 17094439).
WB: Use at a concentration of 1.0 µg/ml.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
FunctionApoptotic suppressor. Has E3 ubiquitin-protein ligase activity. Mediates the proteasomal degradation of target proteins, such as caspase-3, SMAC or AIFM1. Inhibitor of caspase-3, -7 and -9. Mediates activation of MAP3K7/TAK1, leading to the activation of NF-kappa-B.
Involvement in diseaseDefects in XIAP are the cause of lymphoproliferative syndrome X-linked type 2 (XLP2) [MIM:300635]. XLP is a rare immunodeficiency characterized by extreme susceptibility to infection with Epstein-Barr virus (EBV). Symptoms include severe or fatal mononucleosis, acquired hypogammaglobulinemia, pancytopenia and malignant lymphoma.
Sequence similaritiesBelongs to the IAP family. Contains 3 BIR repeats. Contains 1 RING-type zinc finger.
DomainThe first BIR domain is involved in interaction with TAB1/MAP3K7IP1 and is important for dimerization. The second BIR domain is sufficient to inhibit caspase-3 and caspase-7, while the third BIR is involved in caspase-9 inhibition. The interactions with SMAC and PRSS25 are mediated by the second and third BIR domains.
Post-translational modificationsUbiquitinated and degraded by the proteasome in apoptotic cells. Phosphorylation by PKB/AKT protects XIAP against ubiquitination and protects the protein against proteasomal degradation.
Baculoviral IAP Repeat Containing Protein 4 antibody
Baculoviral IAP repeat-containing protein 4 antibody
BIRC 4 antibody
E3 ubiquitin-protein ligase XIAP antibody
IAP 3 antibody
IAP like protein antibody
IAP-like protein antibody
ILP 1 antibody
Inhibitor of apoptosis protein 3 antibody
Inhibitor of Apoptosis X Linked antibody
Mammalian IAP Homologue A antibody
X linked IAP antibody
X linked inhibitor of apoptosis antibody
X linked inhibitor of apoptosis E3 ubiquitin protein ligase antibody
X linked inhibitor of apoptosis protein antibody
X-linked IAP antibody
X-linked inhibitor of apoptosis protein antibody
Anti-XIAP antibody images
Immunocytochemistry/ Immunofluorescence - XIAP antibody (ab2541)This image is courtesy of an Abreview submitted by Dr Kirk McManus
ab2541 (1/200) staining XIAP in HeLa cells (green). Cells were permeabilised with 0.5% Triton-X100/ PBS, fixed in methanol (-20oC, 10min) and counterstained with DAPI (red) in order to highlight the nucleus. Please refer to abreview for further experimental details.
ab2541 staining XIAP in MCF7 cells treated with forskolin (ab120058), by ICC/IF. Increase in XIAP expression correlates with increased concentration of forskolin, as described in literature. The cells were incubated at 37°C for 2h in media containing different concentrations of ab120058 (forskolin) in DMSO, fixed with 100% methanol for 5 minutes at -20°C and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab2541 (1 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.
References for Anti-XIAP antibody (ab2541)
This product has been referenced in:
Hsu KH et al. Anti-apoptotic effects of osteopontin through the up-regulation of Mcl-1 in gastrointestinal stromal tumors. World J Surg Oncol12:189 (2014).
Read more (PubMed: 24947165) »
Lopergolo A et al. Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation. Br J Cancer100:739-46 (2009).
Read more (PubMed: 19223905) »